Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Show More...
-
Website https://www.zealandpharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 453.50 DKK
-
Last Updated 28-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share DKK -5.92 0.6 1.6 -8.1 -2.87 -4.94 -6.33 -9.88 18.94 -16.91 -17.76 Dividends DKK Payout Ratio % * Shares Mil 18.0 22.0 23.0 23.0 23.0 23.0 24.0 28.0 31.0 34.0 35.0 Book Value Per Share * DKK 5.81 19.77 23.72 15.99 13.97 6.7 8.51 20.82 40.39 39.15 32.98 Free Cash Flow Per Share * DKK -3.68 -1.64 2.05 -6.17 -2.46 -9.63 -4.79 -2.62 -13.62 -12.55 Return on Assets % -34.35 2.91 7.34 -42.33 -13.77 -18.51 -23.16 -38.03 59.1 -40.4 -42.82 Financial Leverage (Average) 1.11 1.06 1.06 1.1 2.36 2.52 2.5 1.4 1.1 1.29 1.28 Return on Equity % -38.75 3.15 7.8 -45.51 -22.84 -45.13 -58.03 -67.51 70.68 -48.46 -54.23 Return on Invested Capital % -40.26 2.07 6.63 -46.25 -11.47 -15.29 -20.94 -40.13 71.91 -45.35 -49.92 Interest Coverage 7.86 196.55 -34.94 -2.66 -3.96 -13.69 42.45 -178.93 Current Ratio 10.07 15.99 16.59 10.54 7.5 8.86 4.26 9.28 10.38 7.31 7.3 Quick Ratio 10.04 15.95 16.46 10.42 7.46 8.52 3.95 9.18 10.28 7.16 7.09 Debt/Equity 1.06 1.24 1.18 0.25 0.06 0.08